CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

21-192

APPROVAL LETTER

NDA 20-261/S-028
NDA 21-192

OCT 6 2000

Novartis Pharmaceuticals Corporation
Attention: Adrian L. Birch
Executive Director, Drug Regulatory Affairs
59 Route 10
East Hanover, New Jersey 07936-1080

Dear Mr. Birch:

Please refer to your new drug application (NDA 21-192) dated December 8, 1999, received December 9, 1999, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Lescol XL (fluvastatin sodium extended release tablets), 80mg.

We also refer to your supplemental new drug application (~~NDA~~ 20-261/S-028) dated October 6, 2000, received October 6, 2000, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act which provides for revised labeling for Lescol (fluvastatin sodium) capsules.

We acknowledge receipt of your submissions dated March 1, 21, and 24, April 6, July 19 and 27, August 2, 7, 8, and 25 (2), September 7, 8, and 26, and October 3, 2000.

This new drug application provides for the use of Lescol XL, a new extended release dosage form, as an adjunct to diet to reduce elevated total cholesterol (total-C), LDL-C, TG, and Apo B levels, and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Frederickson Type IIa and IIb) whose response to dietary restriction of saturated fat and cholesterol and other nonpharmacological measures has not been adequate.

This new drug application also provides for the use of Lescol XL to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total and LDL cholesterol to target levels.

NDA 20-261/S-028 provides for combined labeling for the capsule and the extended-release tablet drug products.

We have completed the review of these applications, as amended, and have concluded that adequate information has been presented to demonstrate that the drug products are safe and effective for use as recommended in the agreed-upon labeling text. Accordingly, the applications are approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the submitted draft labeling (package insert submitted October 5, 2000, immediate container and carton labels submitted October 5, 2000). Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit 20 paper copies of the FPL, to each application, as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. Alternatively, you may submit the FPL electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDAs* (January 1999). For administrative purposes, these submissions should be designated "FPL for approved NDA 21-192" and "FPL for approved NDA 20-261/S-028." Approval of this submission by FDA is not required before the labeling is used.

Validation of the regulatory methods for NDA 21-192 has not been completed. At the present time, it is the policy of the Center not to withhold approval because the methods are being validated. Nevertheless, we expect your continued cooperation to resolve any problems that may be identified.

Be advised that, as of April 1, 1999, all applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred (63 *FR* 66632). We note that you have not fulfilled the requirements of 21 CFR 314.55. We are deferring submission of your pediatric studies in patients from 10 to 16 years of age until December 2, 2004. We note that we have previously waived the requirement for pediatric studies in patients younger than 10 years of age.

In addition, please submit three copies of the introductory promotional materials that you propose to use for Lescol XL. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

Please submit one market package of the extended-release tablets product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call William C. Koch, R.Ph., Regulatory Project Manager, at (301) 827-6412.

Sincerely,

/S/

David G. Orloff, M.D.
Director
Division of Metabolic
and Endocrine Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research